Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 Phase 2b placebo-controlled study in adults with Graves' disease
2024-516020-33-00Phase 2Authorised
- Sponsor
- Immunovant, Inc.
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in Graves' disease comparing IMVT-1402 + antithyroid drug with Placebo + antithyroid drug (2 arms). Primary endpoint: Proportion of participants who are euthyroid and off antithyroid drugs at Week 26. Planned start Jun 2025; status: authorised.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on 2024-516020-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516020-33-00.